Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer

Clinica Chimica Acta

Volumn 433, Issue , 2014, Pages 284-289

  Kuo, Yung Bin ^a   Chen, Jinn Shiun ^b,c   Fand, Chung Wei ^b   Li, Yi Shuan ^a   Chan, Err Cheng ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Colorectal cancer; EGFR; KRAS; Mutation; PNA mediated PCR

Indexed keywords

DNA; PEPTIDE NUCLEIC ACID; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; CELL TYPE; CIRCULATING CELL FREE DNA; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DNA DETERMINATION; DNA EXTRACTION; FEMALE; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE SCANNER; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; PRIORITY JOURNAL; TUMOR GENE; VERY ELDERLY; BLOOD; COLORECTAL NEOPLASMS; GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; DNA; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS;

EID: 84899114624     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.03.024     Document Type: Article

References (55)

1. Poston G.J., Figueras J., Giuliante F., et al. Urgent need for a new staging system in advanced colorectal cancer. J Clin Oncol 2008, 26:4828-4833.
2. Chung K.Y., Shia J., Kemeny N.E., et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23:1803-1810.
3. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
4. Ciardiello F., Tortora G. EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
5. Palomba G., Colombino M., Contu A., et al. Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med 2012, 10:178.
6. Qiu L.X., Mao C., Zhang J., et al. Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 2010, 46:2781-2787.
7. Lievre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008, 26:374-379.
8. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008, 26:1626-1634.
9. De Roock W., Claes B., Bernasconi D., et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010, 11:753-762.
10. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
11. Poehlmann A., Kuester D., Meyer F., Lippert H., Roessner A., Schneider-Stock R. K-ras mutation detection in colorectal cancer using the pyrosequencing technique. Pathol Res Pract 2007, 203:489-497.
12. Karapetis C.S., Khambata-Ford S., Jonker D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359:1757-1765.
13. Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009, 360:563-572.
14. Van Cutsem E., Kohne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009, 360:1408-1417.
15. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009, 27:2091-2096.
16. Richman S.D., Chambers P., Seymour M.T., et al. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Pathol (Amst) 2011, 34:61-66.
17. Srinivasan M., Sedmak D., Jewell S. Effect of fixatives and tissue processing on the content and integrity of nucleic acids. Am J Pathol 2002, 161:1961-1971.
18. Emekli-Alturfan E., Kasikci E., Alturfan A.A., Pisiriciler R., Yarat A. Effect of sample storage on stability of salivary glutathione, lipid peroxidation levels, and tissue factor activity. J Clin Lab Anal 2009, 23:93-98.
19. Perkins G., Yap T.A., Pope L., et al. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 2012, 7:e47020.
20. Diehl F., Schmidt K., Choti M.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008, 14:985-990.
21. Frattini M., Gallino G., Signoroni S., et al. Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett 2008, 263:170-181.
22. Lecomte T., Ceze N., Dorval E., Laurent-Puig P. Circulating free tumor DNA and colorectal cancer. Gastroenterol Clin Biol 2010, 34:662-681.
23. Gahan P.B., Swaminathan R. Circulating nucleic acids in plasma and serum. Recent developments. Ann N Y Acad Sci 2008, 1137:1-6.
24. Goebel G., Zitt M., Muller H.M. Circulating nucleic acids in plasma or serum (CNAPS) as prognostic and predictive markers in patients with solid neoplasias. Dis Markers 2005, 21:105-120.
25. Figg W.D., Reid J. Monitor tumor burden with circulating tumor DNA. Cancer Biol Ther 2013, 14:697-698.
26. Schwarzenbach H., Hoon D.S., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011, 11:426-437.
27. Fleischhacker M., Schmidt B. Cell-free DNA resuscitated for tumor testing. Nat Med 2008, 14:914-915.
28. Benesova L., Belsanova B., Suchanek S., et al. Mutation-based detection and monitoring of cell-free tumor DNA in peripheral blood of cancer patients. Anal Biochem 2013, 433:227-234.
29. Demers D.B., Curry E.T., Egholm M., Sozer A.C. Enhanced PCR amplification of VNTR locus D1S80 using peptide nucleic acid (PNA). Nucleic Acids Res 1995, 23:3050-3055.
30. Kyger E.M., Krevolin M.D., Powell M.J. Detection of the hereditary hemochromatosis gene mutation by real-time fluorescence polymerase chain reaction and peptide nucleic acid clamping. Anal Biochem 1998, 260:142-148.
31. Luo J.D., Chan E.C., Shih C.L., et al. Detection of rare mutant K-ras DNA in a single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe. Nucleic Acids Res 2006, 34:e12.
32. Chiou C.C., Luo J.D., Chen T.L. Single-tube reaction using peptide nucleic acid as both PCR clamp and sensor probe for the detection of rare mutations. Nat Protoc 2006, 1:2604-2612.
33. Di Fiore F., Charbonnier F., Lefebure B., et al. Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. Br J Cancer 2008, 99:551-552.
34. Kimura T., Holland W.S., Kawaguchi T., et al. Mutant DNA in plasma of lung cancer patients: potential for monitoring response to therapy. Ann N Y Acad Sci 2004, 1022:55-60.
35. Knijn N., Mekenkamp L.J., Klomp M., et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011, 104:1020-1026.
36. Koffler D., Agnello V., Winchester R., Kunkel H.G. The occurrence of single-stranded DNA in the serum of patients with systemic lupus erythematosus and other diseases. J Clin Invest 1973, 52:198-204.
37. Leon S.A., Shapiro B., Sklaroff D.M., Yaros M.J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977, 37:646-650.
38. Wang J.Y., Yeh C.S., Chen Y.F., et al. Development and evaluation of a colorimetric membrane-array method for the detection of circulating tumor cells in the peripheral blood of Taiwanese patients with colorectal cancer. Int J Mol Med 2006, 17:737-747.
39. Choi J.J., Reich C.F., Pisetsky D.S. The role of macrophages in the in vitro generation of extracellular DNA from apoptotic and necrotic cells. Immunology 2005, 115:55-62.
40. Jahr S., Hentze H., Englisch S., et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 2001, 61:1659-1665.
41. Hibi K., Robinson C.R., Booker S., et al. Molecular detection of genetic alterations in the serum of colorectal cancer patients. Cancer Res 1998, 58:1405-1407.
42. Diehl F., Li M., Dressman D., et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 2005, 102:16368-16373.
43. Diehl F., Schmidt K., Durkee K.H., et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 2008, 135:489-498.
44. Raponi M., Winkler H., Dracopoli N.C. KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 2008, 8:413-418.
45. Plesec T.P., Hunt J.L. KRAS mutation testing in colorectal cancer. Adv Anat Pathol 2009, 16:196-203.
46. Kopreski M.S., Benko F.A., Borys D.J., Khan A., McGarrity T.J., Gocke C.D. Somatic mutation screening: identification of individuals harboring K-ras mutations with the use of plasma DNA. J Natl Cancer Inst 2000, 92:918-923.
47. Mora J., Urgell E., Farre A., Comas L., Montserrat E., Gonzalez-Sastre F. Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer. Clin Chem 2006, 52:1448-1449.
48. Bidard F.C., Weigelt B., Reis-Filho J.S. Going with the flow: from circulating tumor cells to DNA. Sci Transl Med 2013, 5(207):ps214.
49. Morgan S.R., Whiteley J., Donald E., et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. Clin Med Insights Pathol 2012, 5:15-22.
50. Yen L.C., Yeh Y.S., Chen C.W., et al. Detection of KRAS oncogene in peripheral blood as a predictor of the response to cetuximab plus chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res 2009, 15:4508-4513.
51. Baldus S.E., Schaefer K.L., Engers R., Hartleb D., Stoecklein N.H., Gabbert H.E. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010, 16:790-799.
52. Bouchahda M., Karaboue A., Saffroy R., et al. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis. Cancer Chemother Pharmacol 2010, 66:605-609.
53. Saif M.W., Shah M. K-ras mutations in colorectal cancer: a practice changing discovery. Clin Adv Hematol Oncol 2009, 7:45-53. [64].
54. Klein C.A. Parallel progression of primary tumours and metastases. Nat Rev Cancer 2009, 9:302-312.
55. El Messaoudi S., Rolet F., Mouliere F., Thierry A.R. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 2013, 424:222-230.